Evidence map›Paper›PMID 32445881›Full record

ArticleMicrobes and infection

Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.

Ping Xu, Jianping Huang, Zhao Fan, Wendi Huang, Minghua Qi, Xuwen Lin, Weidong Song, Li Yi

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbes and infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 6 pooled it
2.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 6 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. The role of SARS-CoV-2 accessory proteins in immune evasion.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ping XuDepartment of Respiratory and Critical Care Medicine, Peking University Shenzhen, Hospital, Shenzhen, 518036, Guangdong, China.
Jianping HuangDepartment of Infectious Diseases, 433300, Hubei Jianli People Hospital, Hubei, China.
Zhao FanDepartment of Emergency, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Wendi HuangDepartment of Respiratory and Critical Care Medicine, Peking University Shenzhen, Hospital, Shenzhen, 518036, Guangdong, China.
Minghua QiDepartment of Respiratory and Critical Care Medicine, Peking University Shenzhen, Hospital, Shenzhen, 518036, Guangdong, China.
Xuwen LinDepartment of Respiratory and Critical Care Medicine, Peking University Shenzhen, Hospital, Shenzhen, 518036, Guangdong, China.
Weidong SongDepartment of Respiratory and Critical Care Medicine, Peking University Shenzhen, Hospital, Shenzhen, 518036, Guangdong, China. Electronic address: songwd123@hotmail.com.
Li YiDepartment of Neurology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China. Electronic address: pkusz123@sina.com.
Peking University Shenzhen Hospital · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged ≥18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-α2b, monotherapy group patients inhaled IFN-α2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2 b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsBetacoronavirusChinaCoronavirus InfectionsCOVID-19Drug Therapy, CombinationFemaleHumansIndolesInterferon alpha-2Length of StayLymphopeniaMaleAntiviral AgentsIndolesInterferon alpha-2RNA, ViralSulfidesumifenovir2019-nCoVArbidolCOVID-19IFN-α2bPneumoniaRNATreatment

Identifiers

PMID32445881
PMCPMC7238991
OpenAlexW3024946674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.